首页> Cancer> Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.

Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.

导出 LinkOut

翻译打印收藏纠错

第一作者： Alissa J,Cooper

第一单位： Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.

作者： Alissa J,Cooper ^[1] ; Edoardo,Garbo ^[2] ; Andrea,Arfe ^[3] ; Michael,Conroy ^[4] ; Narek,Shaverdian ^[5] ; Matthew,Bott ^[6] ; Teresa,Gorria ^[2] ; Federica,Pecci ^[2] ; Mihaela,Aldea ^[2] ; Valsamo,Anagnostou ^[4] ; Adam,Schoenfeld ^[1] ; Daniel,Gomez ^[5] ; Patrick M,Forde ^[7] ; Mark M,Awad ^[2] ; David R,Jones ^[6] ; Biagio,Ricciuti ^[2] ; Jamie E,Chaft ^[1]

作者单位： Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA. ^[1] Lowe Center for Thoracic Oncology, Dana-Farber Cancer Center, Boston, Massachusetts, USA. ^[2] Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. ^[3] The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. ^[4] Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. ^[5] Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. ^[6] Trinity St James's Cancer Institute, Trinity College, Dublin, Ireland. ^[7]

关键词 locally advanced neoadjuvant chemoimmunotherapy nonsmall cell lung cancer pathologic complete response surgical resectability